Genetics and alzheimer's disease;Genética y enfermedad de alzheimer

Neurologia

Volumn 24, Issue 2, 2009, Pages 83-89

  Manzano, S ^a   Gonzalez J L ^a   Marcos, A ^a   Matias Guiu J ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Alzheimer disease; APOE; Environmental factors; Genetics

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; PRESENILIN 1; PRESENILIN 2;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; PATHOGENESIS; REVIEW;

AGE OF ONSET; ALZHEIMER DISEASE; APOLIPOPROTEINS E; GENETIC PREDISPOSITION TO DISEASE; HUMANS;

EID: 63449103066     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Knopman DS, Dekosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
2. Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di CA, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4-S9.
3. Ott A, Breteler MM, Van HF, Claus JJ, Van der Cammen TJ, Grobbee DE, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 1995;310:970-3.
4. Ramaroson H, Helmer C, Barberger-Gateau P, Letenneur L, Dartigues JF. Prevalence of dementia and Alzheimer's disease among subjects aged 75 years or over: updated results of the PAQUID cohort. Rev Neurol (Paris) 2003;159:405-11.
5. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, Amaducci LA, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 1999;52:78-84.
6. Corrada MM, Brookmeyer R, Berlau D, Paganini-Hill A, Kawas CH. Prevalence of dementia after age 90: results from the 90+ study. Neurology 2008;71:337-43.
7. Jiménez-Escrig A, Barón M. Genetic of dementia. En: Jiménez-Escrig A, editor. Textbook of neurogenetics. Madrid: Díaz de Santos, 2 0 07; p. 213-39.
8. Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M. Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry 2005;62:565-73.
9. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005;115:1449-57.
10. Baiget Bastos M. Aspectos neurogenéticos. En: Manual de demencias. Barcelona: Prous Science, 1996; p. 106-4.
11. Martín JB. Molecular basis of the neurodegenerative disorders. N Engl J Med 1999;340:1970-80.
12. Oliver C, Holland AJ. Down's syndrome and Alzheimer's disease: a review. Psychol Med 1986;1 6:307-22.
13. Goldgaber D, Lerman MI, McBride OW, Saffiotti U, Gajdusek DC. Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease. Science 1987;235:877-80.
14. Bird TD, Sumi SM, Nemens EJ, Nochlin D, Schellenberg G, Lampe TH, et al. Phenotypic heterogeneity in familial Alzheimer's disease: a study of 24 kindreds. Ann Neurol 1989;25:12-25.
15. Hardy J, Duff K. Heterogeneity in Alzheimer's disease. Ann Med 1993;25: 437-40.
16. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6.
17. Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, Tupler RG, et al. Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. Am J Hum Genet 1992;51:273-82.
18. Lemaire HG, Salbaum JM, Multhaup G, Kang J, Bayney RM, Unterbeck A, et al. The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons. Nucleic Acids Res 1989;17:517-22.
19. Yoshikai S, Sasaki H, Doh-ura K, Furuya H, Sakaki Y. Genomic organization of the human amyloid beta-protein precursor gene. Gene 1990;87:257-63.
20. Schubert D, Jin LW, Saitoh T, Cole G. The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron 1989;3:689-94.
21. Esch FS, Keim PS, Beattie EC, Blacher RW, Culwell AR, Oltersdorf T, et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 1990;248:1122-4.
22. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 1992;359:325-7.
23. Anderson JP, Chen Y, Kim KS, Robakis NK. An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence. J Neurochem 1992;59:2328-31.
24. Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. J Neurochem 2005;93:769-92.
25. Mullan M, Houlden H, Windelspecht M, Fidani L, Lombardi C, Díaz P, et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat Genet 1992;2:340-2.
26. The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Alzheimer's Disease Collaborative Group. Nat Genet 1995;11:219-22.
27. Zekanowski C, Styczynska M, Peplonska B, Gabryelewicz T, Religa D, Ilkowski J, et al. Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol 2003;184:991-6.
28. McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006;22:281-9.
29. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry 2007;68:613-8.
30. Lehninger AL NDCC. Biosíntesis de lípidos. En: Omega, editor. Principios de Bioquímica 1993:642-87.
31. Rebeck GW, Kindy M, LaDu MJ. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J Alzheimers Dis 2002;4:145-54.
32. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol Aging 2005;26:355-61.
33. Cummings JL. Definitions and diagnostic criteria. En: Gauthier S DM, editor. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz, 1999: p. 3-15.
34. Dickson DW, Ivanushkin A. Apolipoprotein E immunoreactivity is increased in amyloid deposits of Alzsheimer's disease, but not pathological aging or diffuse Lewy body disease. En: Mortimer A WBWH, editor. Research advances in alzheimer's disease and related disorders. London: Martin Dunitz, 1995: p. 371-83.
35. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
36. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Peri-cak-Vance M, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:8098-102.
37. Li Y, Grupe A. Genetics of late-onset Alzheimer's disease: progress and prospect. Pharmacogenomics 2007;8:1747-55.
38. Cumming AM, Robertson FW. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet 1984;25:310-3.
39. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gas-kell PC, Jr., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-4.
40. Chartier-Harlin MC, Parfitt M, Legrain S, Perez-Tur J, Brousseau T, Evans A, et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum Mol Genet 1994;3:569-74.
41. Zannis VI, Just PW, Breslow JL. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981;33:11-24.
42. Peacock ML, Fink JK. ApoE epsilon 4 allelic association with Alzheimer's disease: independent confirmation using denaturing gradient gel electro- phoresis. Neurology 1994;44:339-41.
43. Fullerton SM, Clark AG, Weiss KM, Nickerson DA, Taylor SL, Stengard JH, et al. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000;67:881-900.
44. Wahlund L. Challenge of the current diagnostic criteria for Alzheimer's Disease. K Iqbal and B Winblad. Alzheimer's Disease and related disorders: research advances. Bucharest: Ana Asian Intl Acad of Aging 2003; p. 103-110.
45. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
46. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-6.
47. Brousseau T, Legrain S, Berr C, Gourlet V, Vidal O, Amouyel P. Confirmation of the epsilon 4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994;44:342-4.
48. Bufill E, Bartes A, Moral A, Casadevall T, Codinachs M, Zapater E, et al. Factores geneticos y ambientales que pueden influir en la forma senil de la enfermedad de Alzheimer: estudio de casos y controles anidado. Neurología 2009;24:108-112.
49. Myers RH, Schaefer EJ, Wilson PW, D'Agostino R, Ordovas JM, Espino A, et al. Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology 1996;46:673-7.
50. Small BJ, Graves AB, McEvoy CL, Crawford FC, Mullan M, Mortimer JA. Is APOE-epsilon4 a risk factor for cognitive impairment in normal aging? Neurology 2000;54:2082-8.
51. Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, et al. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412-5.
52. Corey-Bloom J, Tiraboschi P, Hansen LA, Alford M, Schoos B, Sabbagh MN, et al. E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology 2000;54:403-6.
53. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, et al. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology 1999;53:321-31.
54. Minster RL, Dekosky ST, Kamboh MI. No association of SORL1 SNPs with Alzheimer's disease. Neurosci Lett 2008;440:190-2.
55. Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y, et al. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol 2007;64:501-6.
56. Chapuis J, Hannequin D, Pasquier F, Bentham P, Brice A, Leber I, et al. Association study of the GAB2 gene with the risk of developing Alzheimer's disease. Neurobiol Dis 2008;30:103-6.
57. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007;54:713-20.
58. Rovelet-Lecrux A, Hannequin D, Raux G, Le MN, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38:24-6.
59. Drigalenko E, Poduslo S, Elston R. Interaction of the apolipoprotein E and CI loci in predisposing to late-onset Alzheimer's disease. Neurology 1998;51:131-5.
60. Csaszar A, Kalman J, Szalai C, Janka Z, Romics L. Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. Neurosci Lett 1997;230:151-4.
61. Baron M, Jiménez-Escrig A, Orensanz L, Simon J, Pérez-Tur J. Apolipoprotein E Pittsburgh variant is not associated with the risk of late-onset Alzheimer's disease in a Spanish population. Am J Med Genet B Neuropsychiatr Genet 2003;120B:121-4.
62. Baum L, Wiebusch H, Pang CP. Roles for lipoprotein lipase in Alzheimer's disease: an association study. Microsc Res Tech 2000;50:291-6.
63. Martin-Rehrmann MD, Cho HS, Rebeck GW. Lack of association of two lipoprotein lipase polymorphisms with Alzheimer's disease. Neurosci Lett 2002;328:109-12.
64. Grazina M, Silva F, Santana I, Pratas J, Santiago B, Oliveira M, et al. Mitochondrial DNA variants in a portuguese population of patients with Alzheimer's disease. Eur Neurol 2005;53:121-4.
65. Cai L, Tang G, Chen L, Zhang B, Jiang S, Ren D. Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients. Neuroreport 2005;16:1023-6.
66. Collins JS, Perry RT, Watson B, Jr., Harrell LE, Acton RT, Blacker D, et al. Association of a haplotype for tumor necrosis factor in siblings with late- onset Alzheimer disease: the NIMH Alzheimer Disease Genetics Initiative. Am J Med Genet 2000;96:823-30.
67. Licastro F, Veglia F, Chiappelli M, Grimaldi LM, Masliah E. A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer's disease. Neurobiol Aging 2004;25:1017-22.